filtering structural variants from normal-tumor pairs (whole-genome sequencing)
1
0
Entering edit mode
4.2 years ago
Bogdan ★ 1.1k

Dear all,

we have been sequencing pediatric tumors by using Illumina technology (normal-tumor pairs, paired end reads of 150nt each), and I have been using several SV callers (including DELLY, MANTA, LUMPY) in order to call the Structural Variants.

Considering the initial files of SV calls, what is the set of criteria you would recommend for filtering ? particularly, the number of PR (paired-end reads) or SR (split - reads) ? thank you,

-- bogdan

SV LUMPY DELLY MANTA filtering • 2.0k views
ADD COMMENT
6
Entering edit mode
4.2 years ago
d-cameron ★ 2.3k

This depends on the relative cost of false positives vs false negatives. What FDR and sensitivity are you aiming for?

I've done some fairly extensive benchmarking of SV callers for which you can find germ-line and simulation results at http://shiny.wehi.edu.au/cameron.d/sv_benchmark to given you some idea of the trade-off between FDR and sensitivity for various callers. The DREAM Somatic Mutation Calling Challenge results also give you a basic idea of these trade-offs.

In my somatic usage of GRIDSS, I've found that requiring assembly support has been a very effective filter - something that you could also do for manta. As for direct read support, the relative strength of RP and SR support depends on the library fragment size distribution and will be different for each library. For 2x150bp sequencing, you'll have weak RP support even for real variants in libraries with mean fragment size <300bp. Ideally, you would filter on variant quality directly, instead of RP and SR independently but not many SV callers actually report a variant quality score, and none that I know of report an even remotely calibrated quality score.

Disclaimer: I am the author of GRIDSS.

ADD COMMENT
0
Entering edit mode

Dear Daniel, took a quick look in your paper and it looks fascinating : GRIDSS is among the first algorithms, that combines assembly, SR and PR analysis. Wondering how extensive have you tested it in on cancer samples, for somatic SV detection. We can also take the conversation via email, if you'd like. Thanks.

ADD REPLY

Login before adding your answer.

Traffic: 1134 users visited in the last hour
Help About
FAQ
Access RSS
API
Stats

Use of this site constitutes acceptance of our User Agreement and Privacy Policy.

Powered by the version 2.3.6